Market Updates
Europe Movers: AstraZeneca, Danone, Novartis, SEB
Inga Muller
18 Jul, 2023
Frankfurt
European markets lacked direction and investors remained focused on the start of the corporate earnings season.
The DAX index decreased 0.05% to 16,060.51, the CAC-40 index advanced 0.02% to 7,293.26 and the FTSE 100 index increased 0.05% to 7,410.06.
The yield on 10-year German Bunds inched higher to 2.37%, French bonds traded lower to 2.92%, the UK gilts edged up to 4.37% and Italian bonds increased to 4.02%.
Novartis AG gained 3% to CHF 87.52 after the company lifted its annual earnings outlook and mapped out a plan to spin off its generic pharmaceutical division in the fourth quarter.
The company board also approved the repurchase of $1.5 billion of its stock.
SEB AB declined 0.6% to kr 122.65 in Stockholm trading and the Swedish bank reported earnings ahead of market expectations.
Danone SA declined 0.3% to €55.06 and a day ago Russia announced to takeover a stake held by the company in its Russian subsidiary.
AstraZeneca plc gained 0.5% to 10,250 pence on a report that the U.S. Food and Drug Administration has approved the company and its partner Sanofi's antibody therapy to prevent respiratory syncytial virus in infants and toddlers.
Annual Returns
| Company | Ticker | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|
Earnings
| Company | Ticker | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|